Cellares' recent wins have opened the floodgates for the IDMO
Cellares' recent wins have opened the floodgates for the IDMO
Cellares
Private
Cellares is the first Integrated Development and Manufacturing Organization (IDMO), using an Industry 4.0 approach to mass-manufacture cell therapies. Its Cell Shuttle platform automates and scales the production of CAR-T and other cell therapies, serving clinical and commercial-stage developers.
Company Info
Sector:Biotechnology / Cell Therapy Manufacturing (CDMO)
Headquarters:South San Francisco, California, USA
Founded:2018
Website:www.cellares.com/
Funding Round:Series D (expanded)
Total Funding:~$300M+ reported
Funding & Investor Relations
Notable Investors
- Koch Disruptive Technologies
- Ecosystem Integrity Fund
- DFJ Growth
- Willett Advisors
- Lonergan Partners
- Reciprocal Ventures
IPO Outlook / Plans
Not publicly disclosed
Upcoming Milestones & Key Dates
2026-06-18
Financing
Series D expansion ($50M)
2026-Q3
Capacity expansion
New Bridgewater, NJ site opening
2026-Q4
Operations
First commercial-scale production run for partner CAR-T
Clinical Development Pipeline
Cell Shuttle (Platform)
Target: CDMO platformCellares Mfg Services
Target: Multiple CAR-T/TCRAutomated QC Module
Target: Cell therapy QCRecent News
Cellares, Ori dominate automated cell therapy production: report
A new market report finds Cellares and Ori Biotech dominate the automated cell therapy manufacturing space as CAR-T and TCR therapy developers seek scalable, GMP-grade production platforms.
Leadership Team
Fabian Gerlinghaus
Co-Founder & CEO
Owen Smith
Co-Founder & Chief Business Officer
Alexey Kukaev
Co-Founder & CTO